Evoke Pharma Inc
EVOKDelisted Dec 17, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001403708
Evoke Pharma Inc was delisted on Dec 17, 2025; its insiders filed their last Form 4 on Dec 19, 2025; 15 institutions reported holding it in 13F filings for Q3 2025, worth $2.94M in total; no superinvestor held it.
13F holders, Q3 2024
Institutional positions in Evoke Pharma Inc as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −3 vs. Q2 2024
- Shares held
- 208.3K
- −54.2K (−20.7%) vs. Q2 2024Converted for a 1-for-12 split
- Total value
- $994.6K
- −$672.0K (−40.3%) vs. Q2 2024
- New holders
- 4
- 2 more added
- Sold out
- 7
- 3 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVOK on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 15 | $2.94M |
| Q2 2025 | 10 | $603.6K |
| Q1 2025 | 10 | $678.2K |
| Q4 2024 | 8 | $965.6K |
| Q3 2024 | 12 | $994.6K |
| Q2 2024 | 16 | $1.67M |
| Q1 2024 | 15 | $1.93M |
| Q4 2023 | 11 | $71.8K |
| Q3 2023 | 11 | $92.4K |
| Q2 2023 | 11 | $97.4K |
| Q1 2023 | 12 | $131.1K |
| Q4 2022 | 12 | $161.2K |
| Q3 2022 | 11 | $117.0K |
| Q2 2022 | 13 | $228.0K |
| Q1 2022 | 22 | $987.0K |
| Q4 2021 | 25 | $1.13M |
| Q3 2021 | 23 | $5.46M |
| Q2 2021 | 22 | $6.17M |
| Q1 2021 | 25 | $7.83M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Evoke Pharma Inc; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 70,546 | $338.8K | 0.16% | 00.0% | UnchangedConverted for a 1-for-12 split |
| Bleichroeder LP | 68,750 | $327.3K | 0.09% | 00.0% | UnchangedConverted for a 1-for-12 split |
| Nantahala Capital Management, LLC | 56,249 | $267.7K | 0.02% | 00.0% | UnchangedConverted for a 1-for-12 split |
| Corsair Capital Management, L.P. | 11,667 | $55.5K | 0.01% | +11,667 | New |
| Tower Research Capital LLC (TRC) | 816 | $3.88K | 0.00% | +193+30.9% | AddedConverted for a 1-for-12 split |
| BlackRock, Inc. | 122 | $581 | 0.00% | +122 | New |
| UBS Group AG | 90 | $428 | 0.00% | −2−2.4% | ReducedConverted for a 1-for-12 split |
| Morgan Stanley | 31 | $148 | 0.00% | −0−0.8% | ReducedConverted for a 1-for-12 split |
| Bank of America Corp | 25 | $119 | 0.00% | +19+334.8% | AddedConverted for a 1-for-12 split |
| GWM Advisors LLC | 17 | $81 | 0.00% | −0−1.9% | ReducedConverted for a 1-for-12 split |
| Citigroup Inc | 4 | $20 | 0.00% | +4 | New |
| Danske Bank A/S | 2 | $10 | 0.00% | +2 | New |
| Altium Capital Management LP | 0 | $0 | 0.00% | −57,703−100.0% | Sold outConverted for a 1-for-12 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −4,141−100.0% | Sold outConverted for a 1-for-12 split |
| Vanguard Group Inc | 0 | $0 | 0.00% | −2,488−100.0% | Sold outConverted for a 1-for-12 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −993−100.0% | Sold outConverted for a 1-for-12 split |
| State Street Corp | 0 | $0 | 0.00% | −888−100.0% | Sold outConverted for a 1-for-12 split |
| FMR LLC | 0 | $0 | 0.00% | −6−100.0% | Sold outConverted for a 1-for-12 split |
| Royal Bank of Canada | 0 | $0 | 0.00% | −2−100.0% | Sold outConverted for a 1-for-12 split |
| BlackRock Inc. | – | – | – | – | Not filed |